1
|
Kirkove D, Barthelemy N, Coucke P, Mievis C, Ben Mustapha S, Jodogne S, Dardenne N, Donneau AF, Pétré B. [Feasibility study: The medical imaging as a tool for therapeutic education in radiotherapy]. Cancer Radiother 2022; 26:1034-1044. [PMID: 35843782 DOI: 10.1016/j.canrad.2022.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 03/18/2022] [Accepted: 04/01/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE Assess the feasibility of a randomized controlled trial (RCT) exploring the use of medical imaging as a therapeutic education (TPE) intervention in external radiation therapy. MATERIALS AND METHODS Experimental feasibility trial of "RCT" type carried out in a single-center, between November 2019 and March 2020, following adult patients treated by thoracic radiotherapy. In addition to the information usually given, the experimental group benefited from an intervention consisting in the visualization of their own medical images using the open-source software "Stone of Orthanc". RESULTS Forty-nine patients were recruited with a refusal rate of 8.16% (4/49). 20 patients were withdrawn from the study for health reasons (COVID), 10 for medical reasons. All the remaining 15 participants completed the process. Although not significant, the experimental group showed a median gain in the perception of knowledge compared to the control group (+ 1.9 (1.6 - 2.2)) vs (+ 1.4 (1.4 - 1.8)), as well as a decrease in scores related to anxiety (- 3.0 (-4.5 - (-2.0)) vs - 1.0 (-5.0 - 0.0)) and emotional distress ((- 5.0 (- 7.5 - (- 3.5)) vs (- 2.0 (- 5.0 - (- 1.0)) A significant reduction (p=0.043) is observed for the depression score ((- 2.0 (-3.0 - (-1.5)) vs (0.0 (0.0 - 0.0)). CONCLUSION This study demonstrates the feasibility of the project, with promising preliminary results. Some adaptations in order to conduct a larger-scale RCT are highlighted.
Collapse
Affiliation(s)
- D Kirkove
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique.
| | - N Barthelemy
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - P Coucke
- Département de Physique Médicale, Service médical de radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - C Mievis
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - S Ben Mustapha
- Service Equipe mobile de soins palliatifs, Oncologie Radiothérapie, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman/B35, 4000 Liège, Belgique
| | - S Jodogne
- Institute of Information and Communication Technologies, Electronics and Applied Mathematics, Louvain School of Engineering, 1348 Louvain-la-Neuve, Belgique
| | - N Dardenne
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique; Centre Hospitalo-Universitaire Biostatistique et méthodes de recherche (B-STAT), Faculté de Médecine, Université de Liège, B23/Avenue Hippocrate, n°13, 4000 Liège, Belgique
| | - A-F Donneau
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique; Centre Hospitalo-Universitaire Biostatistique et méthodes de recherche (B-STAT), Faculté de Médecine, Université de Liège, B23/Avenue Hippocrate, n°13, 4000 Liège, Belgique
| | - B Pétré
- Département des Sciences de la Santé Publique, Université de Liège, B23/Avenue Hippocrate, n(o) 13, 4000 Liège, Belgique
| |
Collapse
|
3
|
Challand T, Thureau S, Dubray B, Giraud P. [Esophageal toxicity of radiation therapy: clinical risk factors and management]. Cancer Radiother 2012; 16:364-71. [PMID: 22925486 DOI: 10.1016/j.canrad.2012.07.180] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Accepted: 07/05/2012] [Indexed: 12/25/2022]
Abstract
Acute radiation-induced esophagitis includes all clinical symptoms (odynophagia, dysphagia) occurring within 90 days after thoracic irradiation start. Its severity can be graded using RTOG and CTCAE scales. The clinical risk factors are: age, female gender, initial performance status, pre-therapeutic body mass index, pre-therapeutic dysphagia, tumoral and nodal stage, delivered dose, accelerated hyperfractionned radiotherapy, concomitant association of chemotherapy to radiotherapy and response to the treatment. The dosimetric parameters predictive of esophagitis are: mean dose, V(20Gy), V(30Gy), V(40Gy), V(45Gy) and V(50Gy). Amifostine is the only drug to have a proven radioprotective efficacy (evidence level C, ESMO recommendation grade III). The medical management of esophagitis associates a diet excluding irritant food, medication against gastroesophageal reflux, analgesic treatment according to the WHO scale and management of dehydration and denutrition by enteral feeding.
Collapse
Affiliation(s)
- T Challand
- Département de radiothérapie et de physique médicale, QuantIF, Litis, centre Henri-Becquerel, Rouen, France.
| | | | | | | |
Collapse
|
4
|
Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC – treatment results after long-term follow-up and literature overview. Cancer Radiother 2011; 15:81-8. [DOI: 10.1016/j.canrad.2010.03.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2009] [Revised: 03/12/2010] [Accepted: 03/21/2010] [Indexed: 11/22/2022]
|
6
|
Bera G, Pointreau Y, Denis F, Orain I, Dupuis O, Créhange G. Dose de tolérance à l’irradiation des tissus sains : l’œsophage. Cancer Radiother 2010; 14:327-35. [DOI: 10.1016/j.canrad.2010.02.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2010] [Accepted: 02/02/2010] [Indexed: 12/26/2022]
|
7
|
Martel-Lafay I, Fourneret P, Ayadi M, Brun O, Buatois F, Carrie C, Chilles A, Claude L, Cottin-Durrleman G, Farsi F, Fournel P, Mongodin B, Pouchard I, Balestrière V, Suchaud J. Guide de bonne pratique pour la radiothérapie thoracique exclusive ou postopératoire des carcinomes non à petites cellules. Cancer Radiother 2009; 13:55-60. [DOI: 10.1016/j.canrad.2008.05.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2007] [Revised: 05/07/2008] [Accepted: 05/13/2008] [Indexed: 12/25/2022]
|
8
|
Créhange G, Bonnetain F, Chauffert B, Rat P, Bedenne L, Maingon P. [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?]. Cancer Radiother 2008; 12:365-73. [PMID: 18420440 DOI: 10.1016/j.canrad.2008.02.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2007] [Revised: 02/01/2008] [Accepted: 02/14/2008] [Indexed: 10/22/2022]
Abstract
Adenocarcinoma of the oesophagogastric junction has an ominous prognosis. Until now, oesophageal adenocarcima care was close to the squamous cell cancer one whereas adenocarcinoma of the cardia was mixed with gastric cancers. Results from randomised studies mixed them without making distinctions. Nevertheless, context, natural history and clinical outcome differ. Five-year survival rate is around 40 %, all stages included. Results from several phase-III studies or meta-analysis allowed to define three therapeutic strategies applicable to adenocarcinoma of the oesophagus and the oesophagogastric junction. In Europe, in the case of a resectable tumour, preoperative chemotherapy became a standard treatment since results from the Magic trial. In the United States, post-operative radiochemotherapy according to the "Macdonald" scheme is used in case of a resected tumour with a R0 surgery. Actually, modern techniques of irradiation could reduce the rate of gastro-intestinal toxicities. The survival benefit from preoperative radiochemotherapy is still very controversial with high rates of postoperative morbidity and mortality. We have performed a review of the literature with a methodological analysis of data with a high level of evidence in order to advise perioperative treatment guidelines for patients with a resectable adenocarcinoma of the lower oesophagus or gastro-oesophageal junction. Results from pre- or postoperative strategies and the role of radiotherapy will need to be analysed in the future through a randomised study.
Collapse
Affiliation(s)
- G Créhange
- Département de radiothérapie, centre G.-F.-Leclerc, 1, rue du Pr-Marion, 21000 Dijon, France.
| | | | | | | | | | | |
Collapse
|
9
|
Dubray B, Garcia-Ramirez M, Apardian R. Pour une étude nationale prospective de la toxicité pulmonaire de la radiothérapie. Cancer Radiother 2008; 12:134-5. [DOI: 10.1016/j.canrad.2007.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2007] [Revised: 10/10/2007] [Accepted: 11/28/2007] [Indexed: 10/22/2022]
|